
Merck & Co. MRK
€ 95.08
-0.26%
Geschäftsbericht 2025
hinzugefügt 24.02.2026
Merck & Co. ROCE 2011-2026 | MRK
ROCE Jährlich Merck & Co.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 19.69 | 14.78 | 10.55 | 7.71 | 9.14 | 8.4 | 8.73 | 11.25 | 10.1 |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 19.69 | 7.71 | 11.15 |
ROCE anderer Aktien in der Pharmaeinzelhändler
| Name | ROCE | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
17.8 | $ 21.91 | 2.34 % | $ 1.02 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | ||
|
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
31.5 | $ 22.7 | 3.37 % | $ 3.76 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | ||
|
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | ||
|
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | ||
|
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - | ||
|
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
163.63 | - | -2.5 % | $ 5.88 M | ||
|
Applied Therapeutics
APLT
|
394.73 | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | ||
|
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
123.77 | - | 17.91 % | $ 11.1 M | ||
|
BioNTech SE
BNTX
|
-4.81 | $ 102.78 | -2.55 % | $ 27.2 B | ||
|
Avenue Therapeutics
ATXI
|
-168.29 | - | -52.27 % | $ 4.45 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
211.07 | $ 4.16 | 1.84 % | $ 445 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 23.75 | 2.09 % | $ 3.02 B | ||
|
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M | ||
|
Autolus Therapeutics plc
AUTL
|
-151.88 | $ 1.45 | 0.35 % | $ 386 M | ||
|
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | ||
|
AstraZeneca PLC
AZN
|
11.12 | - | - | $ 96.9 B | ||
|
AVROBIO
AVRO
|
10.76 | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 3.03 | 4.12 % | $ 4.99 M | ||
|
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B | ||
|
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | ||
|
bluebird bio
BLUE
|
-125.56 | - | - | $ 546 M | ||
|
ContraFect Corporation
CFRX
|
545.12 | - | -5.16 % | $ 5.39 M | ||
|
Cardiff Oncology
CRDF
|
-107.87 | $ 1.76 | 2.03 % | $ 118 M | ||
|
BioXcel Therapeutics
BTAI
|
52.86 | $ 1.11 | 4.25 % | $ 13.6 M | ||
|
Cabaletta Bio
CABA
|
-153.72 | $ 3.02 | 2.43 % | $ 303 M | ||
|
Cara Therapeutics
CARA
|
-127.7 | - | -3.03 % | $ 260 M | ||
|
Allena Pharmaceuticals
ALNA
|
-252.54 | - | 3.16 % | $ 1.9 M | ||
|
CASI Pharmaceuticals
CASI
|
-49.51 | - | - | $ 35.4 M | ||
|
CymaBay Therapeutics
CBAY
|
-34.79 | - | - | $ 3.45 B |